debt_leverage_profile
Highly leveraged micro-cap with minimal revenue; 20% rate increase would materially stress already thin liquidity and likely require equity dilution to service debt.
Inferred
Agent_Inference
interest_rate_sensitivity
Extremely high sensitivity; company relies on convertible notes and equity raises, so rising rates increase borrowing costs and reduce refinancing flexibility significantly.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Cannabis cultivation inputs dependent on Canada-US border flows; pharmaceutical-grade extraction chemicals subject to DEA/Health Canada regulatory chokepoints.
Inferred
Agent_Inference
international_expansion_readiness
Operations primarily in Canada and Latin America (Colombia); Colombian peso devaluation risk is significant given early-stage revenues denominated in local currency.
Inferred
Agent_Inference
geographic_footprint
Canada (primary) and Colombia (secondary); peso and CAD exposure present; limited revenue diversification makes currency devaluation in either market highly impactful.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Likely yes; small cannabis operators typically depend on single licensed cultivation or extraction partners exceeding 30% of input costs with limited substitutes.
Inferred
Agent_Inference
business_model_type_primary
Not a cloud-dependent business; operations are physical cannabis cultivation, processing, and pharmaceutical distribution—cloud termination would cause administrative disruption only.
Inferred
Agent_Inference
business_model_type_secondary
Secondary impact limited to CRM, ERP, and compliance software; no core revenue generation is cloud-infrastructure dependent.
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; company does not appear to rely on proprietary third-party APIs for core operations; regulatory compliance software switching cost is moderate.
Inferred
Agent_Inference
howey_test_risk_index
Low Howey Test risk; revenue model is product sales (cannabis/pharmaceuticals), not investment contracts; no token or profit-sharing scheme identified.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR/CCPA exposure; patient and customer health data in Canada and Colombia subject to PIPEDA and local health privacy laws; GDPR risk low given minimal EU operations.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; company is a micro-cap with negligible market share in fragmented cannabis and pharmaceutical markets; no dominant position to defend.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional; product sales of cannabis and pharmaceutical goods with no significant recurring subscription or multi-year contract revenue base identified.
Inferred
Agent_Inference
monetization_vector
Direct B2B and B2C product sales of cannabis-derived pharmaceuticals and raw cannabis; wholesale distribution to dispensaries and healthcare providers.
Inferred
Agent_Inference
pricing_architecture
Commodity-like pricing vulnerable to market price compression; cannabis wholesale prices have declined industry-wide, limiting ability to sustain margins under stress.
Inferred
Agent_Inference
pricing_power_rating
Very low; cannabis and pharmaceutical generics face intense price competition; company lacks brand differentiation or proprietary formulations to command premium pricing.
Inferred
Agent_Inference
target_gross_margin_bracket
-153.1% Gross Margin (Negative equity)
High
SEC-XBRL
churn_vulnerability_index
Minimal free-rider risk; physical product sales model has no digital content or platform leakage; churn risk stems from distributor relationship fragility.
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is largely headcount-linear; cultivation, processing, and distribution operations require proportional labor increases as output scales.
Inferred
Agent_Inference
marginal_cost_of_growth
High marginal cost of growth; scaling requires capital-intensive facility expansion, additional licensed staff, and regulatory approvals—no software-like leverage.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; company does not operate a franchise model.
Inferred
Agent_Inference
customer_acquisition_metric
Unit economics at 10x scale unproven; current CAC and LTV data not publicly disclosed; regulatory expansion costs would likely compress margins at scale.
Inferred
Agent_Inference
network_effect_present
No network effects present; cannabis cultivation and pharmaceutical distribution is a linear supply chain with no user-growth multiplier effect.
Inferred
Agent_Inference
asset_efficiency_ratio
-121.6% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate recession resistance; medical cannabis demand is relatively inelastic, but discretionary adult-use and early-stage pharma revenues are vulnerable to consumer pullback.
Inferred
Agent_Inference
customer_segment_primary
Medical cannabis patients and licensed healthcare distributors in Canada and Colombia; likely high concentration among a few wholesale buyers.
Inferred
Agent_Inference
customer_segment_secondary
Government health agencies and regulated dispensary networks; loss of any single government contract could represent outsized revenue impact given small revenue base.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.4% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001081938
High
SEC-EDGAR
ticker
CPMD
High
SEC-EDGAR